<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01064453</url>
  </required_header>
  <id_info>
    <org_study_id>14841</org_study_id>
    <secondary_id>AQ0710KR</secondary_id>
    <nct_id>NCT01064453</nct_id>
  </id_info>
  <brief_title>Angeliq Regulatory Post Marketing Surveillance</brief_title>
  <acronym>Angeliq rPMS</acronym>
  <official_title>Angeliq Regulatory Post Marketing Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy
      in real practice for the indication approved by Korea Food and Drug Administration (KFDA).
      This is non-interventional , prospective, multi-center study.Target number of patients is
      4500.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event collection</measure>
    <time_frame>At each visit of patient during observational period (6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of menopausal symptoms</measure>
    <time_frame>After 6 months or at discontinuation of Angeliq (At earlier point)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4078</enrollment>
  <condition>Postmenopausal Period</condition>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2/DRSP (Angeliq, BAY86-4891)</intervention_name>
    <description>Take one tablet daily, continuously</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Korean women who take Angeliq for postmenopausal symptoms or/and prevention of osteoporosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hormone replacement therapy for estrogen deficiency symptoms in postmenopausal women
             more than 1 year postmenopause

          -  Prevention of osteoporosis in postmenopausal women at high risk of future fractures
             who are intolerant of, or contraindicated for, other medicinal products approved for
             the prevention of osteoporosis

        Exclusion Criteria:

          -  Undiagnosed genital bleeding

          -  Known, past or suspected cancer of the breast

          -  Known or suspected estrogen-dependent malignant tumors (e.g. endometrial cancer)

          -  Untreated endometrial hyperplasia

          -  Previous idiopathic or current venous thromboembolism (e.g. deep venous thrombosis,
             pulmonary embolism)

          -  Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction)

          -  Acute liver disease, or a history of liver disease as long as liver function tests
             have failed to return to normal

          -  Porphyria

          -  Severe renal insufficiency or acute renal failure

          -  Known hypersensitivity to the active substances or to any of the excipients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2010</study_first_submitted>
  <study_first_submitted_qc>February 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2010</study_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menopause</keyword>
  <keyword>Menopausal symptoms</keyword>
  <keyword>Prevention of osteoporosis in menopausal women</keyword>
  <keyword>Estrogen deficiency symptoms</keyword>
  <keyword>Hormone replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

